Despite its potential, ADCC faces several challenges. Tumor cells may develop resistance by downregulating the expression of target antigens or shedding these antigens to evade immune detection. Additionally, the tumor microenvironment may suppress effector cell activity through various immunosuppressive factors. Variability in Fc receptor polymorphisms among patients can also affect the efficacy of ADCC-based therapies.
